Terzepatide in HFpEF: A Cardiology Review

Created using ChatSlide

This lecture reviews tirzepatide as a cardiometabolic strategy for obesity-related HFpEF. It explains the therapeutic rationale, dual GIP/GLP-1 mechanism, SUMMIT trial design and outcomes, CMR evidence of reverse remodeling, and links between adipose reduction, LV mass regression, and clinical benefit. Safety, tolerability, and practical integration with HFpEF therapies are highlighted.